In the early part of this century several attempts were made to immunize human beings against beta hemolytic streptococci (1-4). These attempts generally were considered to be unsuccessful. The results were difficult to evaluate, however, because of the multiplicity and toxicity of streptococcal antigens and the limited understanding of their relationship to virulence. Subsequently, immunity was correlated with antibody against type specific M protein contained in streptococcal cell walls (5-9), and sensitive methods were developed for the assay of these type specific antibodies (6, 7).
mately half of the patients who initially developed immune response to their infections. Advantage was taken of this situation to determine whether or not small doses of streptococcal cell walls were sufficiently antigenic to recall antibody of homologous type. A positive outcome might encourage further attempts at primary immunization with similar preparations.
The following report will show that type specific antibody was readily recalled in human beings by the administration of small, well tolerated doses of vaccines prepared from streptococcal cell walls.
METHODS
Preparation of vaccine. Strain SF42 of type 12 streptococci was employed to prepare cell wall vaccine. This strain, originally isolated by Griffith in 1934 from a patient with scarlet fever (18) , was supplied to us as a lyophilized culture by Dr. Rebecca Lancefield in 1956 . At that time it contained a large amount of group A polysaccharide. After several mouse passages in this laboratory, it mutated to a variant which no longer contained group A antigen but, rather, the polysachharide designated "V" (variant) antigen by McCarty and Lancefield (19) . This strain was selected for preparation of the vaccine because large amounts of type 12 M protein were present in the organisms and because the absence of group A polysaccharide was considered to be of possible advantage in reducing toxic reactions.
Type 5 cell wall vaccine was prepared with a group A strain, S1624, which had been isolated 2 years previously from a patient with pharyngitis at Children's Memorial Hospital, Chicago, Ill. Virulence and high M protein content had been maintained by frequent mouse passage.
Organisms for the preparation of vaccine were grown in 3-L lots of commercial Todd-Hewitt broth (Difco) which was modified by the addition of phosphate-buffered glucose (20) to contain approximately 1.5 per cent of the sugar. Cell walls then were prepared by the method of Barkulis and Jones (21) with minor modifications. Streptococci were harvested by centrifugation and washed 3 times in approximately 20 vol of distilled water. The cells were then suspended in distilled water in a concentration of 10 per cent by wet weight.
Aliquots (5 ml) of this suspension were agitated in a Mickle disintegrator with 5 mg of no. 12 Ballotini glass beads.1 Each lot was examined microscopically to determine when fragmentation of the cells had occurred.
A period of 20 minutes in the distintegrator at an amplitude of approximately 1.5 cm and a frequency of 60 times a second usually was adequate. The beads were removed from the cell walls by means of a coarse fritted glass filter. The cell walls then were centrifuged at 16,000 G for 30 minutes at 40 C, resuspended in approximately 100 vol of 0.2 M phosphate buffer, pH 7.4, by mixing in a Waring Blendor for 30 seconds, and centrifuged again at 16,000 G for 30 minutes. The cell walls were washed in this fashion five times in phosphate buffer and a sixth time in distilled water. They were finally suspended in 100 ml of pyrogen-free, normal saline with 0.9 per cent benzyl alcohol, autoclaved at 15 pounds of pressure for 15 minutes, quickly frozen in a dry ice-alcohol bath and stored at -700 C as stock vaccine.
One-ml aliquots of these stock suspensions were found to contain 3 to 4.5 mg of cell walls by dry weight and 218 to 276 /Ag of nitrogen by micro-Kjeldahl analysis.
Dilutions containing the desired amounts of cell wall nitrogen were made from these stock suspensions and tested for sterility shortly before their use in vaccination.
M protein and group specific carbohydrate were extracted from 1-ml aliquots of vaccine by the method of Swift, Wilson and Lancefield (22) . The resulting extracts reacted strongly (3 to 4 plus) with homologous antisera to type 12 and type 5 M proteins, respectively, and less strongly with antisera to the variant and group A carbohydrates, respectively. Ultraviolet absorption spectra of these extracts also were studied to determine to what extent the cell walls had been freed from nucleoproteins. The relative concentration of nucleic acid to protein in the extracts varied from 5 to 8 per cent as determined by the ratio of the optical densities at 2,800 and 2,600 A (23).
Immuniztation procedure. Vaccine was administered to patients selected from a controlled study of streptococcal pharyngitis in progress at Children's Memorial Hospital since 1956. The protocol of this study has been described in detail elsewhere (16) . Intradermal skin tests with cell wall suspensions containing at least 0.05 /ug nitrogen were made in all patients prior to vaccination. The sites were examined for reactions at 30 hours. Patients with induration or erythema of more than 1 cm in diameter were not vaccinated. When no induration or erythema was present, 50 times the skin test dose was administered subcutaneously. When induration or erythema of 1 cm or less was noted, 10 times the skin test dose was given subcutaneously. Subsequent weekly injections, with increments of 2 to 5 times the previous dose, were administered according to each patient's tolerance. The total subcutaneous dose, therefore, varied with each individual and ranged from 8 to 56 ,ug of cell wall nitrogen. In 8 patients all injections of vaccine were administered intradermally. These patients received 1 to 7,g of cell wall nitrogen divided into 4 or 5 injections. At the first visit the patient was examined, his throat was cultured, and blood was drawn for type specific antibody determination. Throat cultures were made at each subsequent visit to exclude the possibility that unapparent streptococcal infections, rather than vaccine, might boost antibody titers. Blood was drawn again for type specific antibody assay 1 week after the last inj ection.
Assay of sera for type specific antibody. Type specific antibody titer was determined by two methods used routinely in this laboratory-the bactericidal test modified slightly from that described by Lancefield (24) , and the long chain test described by Stollerman and Ekstedt (25) . A positive bactericidal test depended upon opsonization of the streptococci by immune serum and their subsequent phagocytosis by the normal control blood. The bactericidal index was used as an expression of the opsonic activity of antibody to M protein (24) . This was derived by comparing the growth rates of virulent streptococci in "normal" human blood, which contained no homologous type specific antibody, with the same blood to which the test serum was added. An index of 100, for example, indicated that growth was 100 times greater in the control blood than in the same blood to which the test serum was added. Bactericidal indices of less than 10 were not considered significant, 10 to 25 were considered to be due to traces of M antibody, 25 to 100 were weakly positive, 100 to 500 positive, and greater than 500 strongly positive. The chain length index was derived from the ratio of the mean chain length of streptococci grown in the test serum to the mean chain length of the same organisms grown in normal rabbit serum. Because virulent encapsulated streptococci grow in long chains in the presence of homologous type antiserum, and in very short chains in serum which does not contain type specific antibody, this index is a semiquantitative expression for the amount of anti-M antibody in the system. A threefold increase in mean chain length (index = 3), or greater, was considered a statistically significant test for type specific antibody (26, 27) .
During these studies, it became apparent that the many variables of the bactericidal and long chain tests were particularly important in assays of sera in which type specific antibody was present in very low titer. The size of the inoculum was critical. Dilutions containing 10 to 150 organisms in 0.1 ml broth were optimal inocula for the demonstration of small amounts of type specific antibody by the bactericidal test. When heavier suspensions were employed, the extracellular streptococci multiplied rapidly and obscured the opsonic effect of the antiserum. A minimal inoculum of approximately 10,000 organisms was required in the long chain test in order to count sufficient numbers of streptococci conveniently. Thus, a larger amount of antibody was necessary to demonstrate long chain growth. At critical levels, therefore, the bactericidal test could be positive and the long chain test negative. Occasionally, the reverse situation could occur due to nonspecific factors affecting phagocytosis (26, 27) . The degree of virulence of the test strain of streptococci also had an effect on the resulting indices when titers of serum antibody were low (Table I) . Similar observations on bactericidal tests (28) and on long chain tests (27) have been reported by others. Organisms of moderate virulence were required for assay of low levels of type specific antibody, but were difficult to maintain in this phase. Two or three passages of virulent type 12 streptococci through Todd-Hewitt broth frequently resulted in dissociation of the strain to an avirulent phase. In contrast, highly virulent organisms emerged after daily passage through mice or through fresh human blood which was rotated for 4 Skin tests were repeated 1 year after vaccination in eight patients. The reaction in five patients was unchanged. An increase in induration of 1 to 2 cm was observed in three individuals. Two of these subjects had received the vaccine intracutaneously.
Immune response to cell wall vaccine in normal adults. The three adults who were studied for tolerance to vaccine served also as subjects for a pilot study of been demonstrated after infection. Ten children titers were equal to or greater than the titers which were selected who had formerly developed un-had followed the natural infections. The recalled mistakable type 12 antibody responses after type antibodies decreased to prevaccination levels 12 streptococcal pharyngitis, but in whom the within 6 months. Patient 8 in Table IV was the titer of this antibody subsequently disappeared sole exception to the above observations. In this (seven patients) or diminished considerably patient, antibody was still present in relatively (three patients) during the following 2 years high titer at the time of vaccination. Antibody (Table III) . levels increased only slightly after vaccination. Type 12 antibody was recalled or boosted in all The titer was still increased 6 months later. of these patients after doses of 4 to 44 /Ag cell wall Immune response to cell wall vaccine in panitrogen, given in three or four injections at tients with previous streptococcal infections folweekly intervals (Table IV) . Antibody appeared lowed by little or no demonstrable type specific within 3 weeks from the onset of the course of antibody. A group of ten patients was selected to injections and was found to be type specific when explore the possibility that their previous infectested with heterologous organisms. When tested tions might have provoked primary immune reby serial dilutions of the sera, the post-vaccination sponses even though these could not be demon- (14, 15) . (32, 33) .
In future studies of primary immunization it would be helpful to exclude patients who have been naturally immunized previously with the homologous type of streptococcus. This can be done by preliminary administration of booster doses of vaccine as described in this study. Those who fail to respond to such doses might be considered suitable subjects for studies of primary immunization. A study employing this procedure is in progress.
SUM MARY
Cell walls of type 12 and type 5 streptococci were tested for antigenicity in human beings with and without previously documented infections of homologous type. Minute doses of M protein present in streptococcal cell wall vaccines were shown to be capable of producing a secondary type specific immune response in human beings when administered in three or four weekly, well tolerated, subcutaneous or intradermal doses.
Type specific antibodies were boosted or recalled in all patients who previously had had unmistakable primary immune responses to natural infections but whose serum titers had subsequently declined to low levels or disappeared. Secondary responses to vaccination also were elicited readily when antecedent infections had been followed by the appearance of only traces of serum antibody, and in some instances, when no circulating antibody had been detected.
Type 12 antibody responses to cell wall vaccine were elicited in 7 of 14 patients who had no prior history of infection with this type and whose preimmunization sera contained either no detectable antibody or only traces thereof.
The implications of these findings with regard to primary artificial immunization against group A streptococci, and the application of booster vaccination as a method for determining previous infection with a given streptococcal serotype are discussed.
